Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Dermatophytic Onychomycosis Treatment Market size was valued at USD 3.4 billion in 2024 and is projected to reach USD 7.9 billion by 2037, rising at a CAGR of 9.1% during the forecast period from, 2025-2037. In 2025, the industry size of dermatophytic onychomycosis treatment estimated at USD 3.6 billion.
The dermatophytic onychomycosis treatment market comprises a robust patient pool, which is estimated to account for 375 to 450 million cases, with an increase in the aging population, especially across regions with a humid climate. Besides, as per reports published by the CDC and NIH, approximately 15.5% of adults in developed countries and 20% to 22% in tropical locations are severely affected by the condition, owing to which there is a huge demand for the market internationally. Besides, the supply chain aspect for treatments comprises active pharmaceutical ingredients (APIs) that are readily sourced from China, accounting for 40.5% of worldwide antifungal API manufacturing, and 25.7% from India, and further followed by the EU and the U.S.
Furthermore, the producer price index has risen by 4.3%, which is effectively driven by disruptions in the supply chain along with fluctuations in API spending. On the other hand, the consumer price index has increased by 6.2% for onychomycosis treatments, which reflects a surge in research and development expenditure. Besides, the funding for private and public research and development has also reached USD 1.3 billion in 2024, out of which 67.5% has been allocated to novel topical formulations. Meanwhile, the international trade for finished drugs and antifungal raw materials was worth USD 6.1 billion in 2023, with the EU and the U.S. as notable importers. Additionally, China exports USD 1.5 billion antifungal APIs, thereby suitable for the market growth.
Dermatophytic Onychomycosis Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Cost-effective interventions and improvement in health quality: The aspect of global healthcare systems is effectively prioritizing early adherence programs and diagnosis to combat high costs. As per a clinical study conducted by the AHRQ in 2022, early topical treatment diminished hospitalizations in the U.S. by almost 28.5%, which saved USD 955 million for almost two years. Besides, telemedicine follow-ups have enhanced adherence by an estimated 35% by streamlining patient monitoring procedures, thereby suitable for the dermatophytic onychomycosis treatment market globally.
- Unmet demands in developing markets: There is a presence of accessibility and affordability gaps in the overall dermatophytic onychomycosis treatment market, especially in Latin America, Africa, and Asia. For instance, rural areas in India comprise 85% of untreated cases, accounting for a USD 1.7 billion opportunity for generics, which constitutes a huge opportunity for the dermatophytic onychomycosis treatment market upliftment. Besides, to cater to the unmet needs, there has been an allocation of USD 123.5 million by the SUS program in Brazil with the objective to increase medical accessibility, thus suitable for market growth.
Historical Patient Growth Analysis Shaping the Dermatophytic Onychomycosis Treatment Market
The worldwide dermatophytic onychomycosis treatment market has been reshaped with an expansion in the sustained patient pool, highly attributed to an increase in diabetes occurrence, improvement in diagnostic capabilities, and a surge in the aging population. Besides, developed markets, such as Japan, Germany, and the U.S., witnessed an annual growth ranging from 4% to 8% between 2014 and 2024 in regard to diagnosed cases. Meanwhile, developing nations, including China and India, have experienced a 7% to 11% growth rate, owing to enhanced health and medical accessibility, along with urbanization, thus denoting an optimistic outlook for the overall market.
Historical Patient Growth (2014–2024) in Key Markets
|
Country |
2014 Patients (Million) |
2024 Patients (Million) |
CAGR (%) |
Key Driver |
|---|---|---|---|---|
|
U.S. |
23.6 |
35.3 |
4.5% |
Medicare Part D expansion |
|
Germany |
3.3 |
5.1 |
5.2% |
Podiatry reimbursement reforms |
|
France |
2.9 |
4.5 |
5.3% |
Geriatric screening programs |
|
Spain |
2.2 |
3.6 |
5.6% |
OTC antifungal deregulation |
|
Australia |
1.8 |
2.8 |
4.8% |
PBS-listed topical treatments |
|
Japan |
6.5 |
9.1 |
3.9% |
Aging population (29.2% >65) |
|
India |
18.3 |
32.9 |
6.6% |
Urbanization + diabetes surge |
|
China |
21.6 |
38.6 |
6.4% |
Retail pharmacy expansion |
Key Feasible Expansion Models Shaping the Future of Dermatophytic Onychomycosis Treatment
The global dermatophytic onychomycosis treatment market is rapidly undergoing transformation due to OTC deregulation, integration of telemedicine services, and the existence of public and private partnerships. For instance, suppliers are deliberately partnering with AYUSH Ministry clinics in India with the ultimate aim to supply cost-effective and affordable terbinafine, which has enhanced treatment rates by 19.5%, especially in rural areas. Besides, Medicare telehealth waivers in the U.S. have bolstered prescription adherence by 27.8%, thereby diminishing relapse costs by USD 305 million per year. Therefore, all these models are effective and readily drive the market demand across different nations.
Feasibility Models for Market Expansion
|
Model |
Region |
Key Metric |
Impact (2022–2024) |
|---|---|---|---|
|
PPPs + generics |
India |
12.5% revenue growth |
USD 223.6 million → USD 247. 5 million |
|
Medicare telehealth |
USA |
27.8% adherence improvement |
USD 1.3 billion → USD 1.8 billion |
|
OTC deregulation |
Spain |
33.2% volume increase |
4.5 million → 5.7 million units |
Challenges
- Barriers in diagnostic services: The aspect of restricted accessibility and misdiagnosis in evaluation suppresses the dermatophytic onychomycosis treatment market. According to a report published by the AAD in 2023, an estimated 44% of onychomycosis cases have been dismissed as cosmetic, while there is a lack of PCR or laboratory infrastructure to confirm infections, all of which negatively impact the market development. Besides, the U.S. has observed 35% of false negatives with KOH evaluations, which result in delayed treatment for more than 7 months. However, organizations, such as Bausch Health, are integrating AI-driven imaging tools to overcome these barriers, thus suitable for market growth.
- Competition among generics: Substandard generics readily dominate LMICs, resulting in undermining trust in therapies, which denotes a negative impact on the dermatophytic onychomycosis treatment market. For instance, as stated in the 2023 CDSCO report, almost 28% to 35% of generics in India failed dissolution tests, and WHO prequalification remained rare for antifungals. However, key players, including Lamisil, overcame this challenge by implementing anti-counterfeit packaging, but with the presence of price-specified procurement by LMIC administrative organizations, thus prolific for the market internationally.
Dermatophytic Onychomycosis Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.1% |
|
Base Year Market Size (2024) |
USD 3.4 billion |
|
Forecast Year Market Size (2037) |
USD 7.9 billion |
|
Regional Scope |
|
Dermatophytic Onychomycosis Treatment Segmentation
Treatment Type (Oral Antifungals, Topical Antifungals, Laser Therapy, Surgical Intervention)
Based on the treatment type, the oral antifungals segment is projected to hold the largest share of 45.8% in the dermatophytic onychomycosis treatment market by the end of 2037. The segment’s growth is highly attributed to the aspect of established clinical guidelines and their systemic efficacy. According to the 2024 NIH report, terbinafine accounts for an estimated 67% of the segment’s sales, owing to suitable cure rates of 88% and cost-effectiveness, constituting USD 0.55 per day treatment costs. Besides, the segment’s upliftment is also supported by an increase in geriatric population, especially in developed countries, wherein oral formulations are highly preferable thereby encouraging market growth.
Route of Administration (Topical, Oral, Injectable)
Based on the route of administration, the topical segment is anticipated to hold the second-largest share of 36.5% in the dermatophytic onychomycosis treatment market during the forecast timeline. This growth is fueled by a boost in applications for mild-to-moderate infections, along with the aspect of the safety profile. A few notable topical formulations, such as tavaborole and efinaconazole, both combinedly demonstrate almost 64% to 74% efficacy rates with nominal systemic side effects. Besides, the latest innovations in drug delivery systems, including nail-penetrating solutions and microneedle patches, have successfully enhanced bioavailability by 42%, thus suitable for market upliftment.
Our in-depth analysis of the dermatophytic onychomycosis treatment market includes the following segments:
|
Treatment Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportDermatophytic Onychomycosis Treatment Industry - Regional Synopsis
North America Market Analysis
North America in the dermatophytic onychomycosis treatment market is projected to account for the highest share of 42.8% during the forecast period. The region’s growth is effectively fueled by an increase in treatment adoption rates as well as a strong presence of health and medical infrastructure. Besides, the U.S. is leading with 87% of the overall regional demand, highly attributed to Medicare coverage services. Moreover, the telemedicine integration has bolstered prescription rates in the region by almost 19.3% since 2022, thus creating a positive impact on the market upliftment.
The dermatophytic onychomycosis treatment market in the U.S. is effectively driven by the presence of reimbursement facilities. For instance, the Medicare coverage in the country has increased, with USD 850 million in spending in 2024, further constituting a 16.5% growth since 2020. Additionally, there has been an allocation of USD 1.3 billion for enhancing accessibility, especially for low-income patients, which has boosted the market exposure in the country. Moreover, the country takes into consideration FDA approvals that positively drive the market demand and cater to required services.
The dermatophytic onychomycosis treatment market in Canada is also growing significantly and is readily shaped by provincial health and medical investments. For instance, between 2021 and 2024, there has been a surge in spending in Ontario by 18.5%, which majorly contributes to the market upliftment in the country. Besides, topical therapy solutions are leading, owing to reduced side effects. Also, there has been a rise in telemedicine adoption, with an estimated 26% of patients in rural areas easily accessing diagnostics. Meanwhile, generic competition effectively keeps price strategies low, thus suitable for dermatophytic onychomycosis treatment market development.
Europe Regional Market Size & Growth
Europe in the dermatophytic onychomycosis treatment market is expected to account for a considerable share of 30.9% by the end of the forecast period. This growth is highly attributed to a robust healthcare system, a rise in the occurrence of diabetes, and a surge in the elderly population. In addition, the market in the region is further characterized by the increased implementation of advanced therapies and stringent reimbursement policies. Besides, Germany is leading, with a yearly allocation of €4.2 billion, while the UK and France have prioritized telemedicine adoption to improve accessibility, thereby creating a huge opportunity for the market growth and expansion in the region.
The dermatophytic onychomycosis treatment market in Germany is dominating the region, and is readily projected to capture approximately 34% of the overall regional revenue by the end of 2037. This growth is fueled by the presence and availability of proactive administrative policies. For instance, the provision of €4.4 billion for ensuring antifungal treatments has resulted in a 13.2% growth rate. This, in turn, has facilitated AMNOG reforms, which have prioritized cost-effective generics. Besides, the country has readily shifted its focus to early intervention to provide national diabetes screening programs, that has identified 500,200 potential cases, thereby driving the market demand.
The dermatophytic onychomycosis treatment market in the UK accounts for 27% of the overall market share, due to digital health intervention and a surge in NHS coverage. For instance, as per an article published by the NHS in 2023, NHS England has provided £1.4 billion, which is 8.2% of its drug budget, to onychomycosis. This has enabled more than 500,320 patients to gain access to terbinafine. Besides, tele-dermatology has effectively diminished the delay in diagnosis by 41%, owing to the implementation of AI-based tools such as DermaScan, which has enhanced detection rates by 33% in rural parts of the country, thus denoting a positive contribution towards the market.
Companies Dominating the Dermatophytic Onychomycosis Treatment Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The global dermatophytic onychomycosis treatment market is considered to be extremely competitive, with the comprehensive presence of key players. For instance, Pfizer holds a share of approximately 22%, followed by a 13.1% share of Novartis AG, based on catering to topical and oral antifungals. Besides, Bausch Health readily dominates the overall market with a 9.2% share, especially in the premium topical segment by unveiling Jublia. Meanwhile, organizations in India, such as Dr. Reddy’s and Glenmark, combinedly captured a 17% share through low-cost alternatives. Other tactical strategies, including fast-track designations, expansion in emerging economies, and OTC switches, are positively impacting the market growth across different nations.
Here is a list of key players operating in the global dermatophytic onychomycosis treatment market:
|
Company Name (Country of Origin) |
Industry Focus & Notable Products |
Market Share (2024) |
|---|---|---|
|
Pfizer Inc. (U.S.) |
Oral antifungals (Lamisil), market leader in terbinafine |
18.6% |
|
Novartis AG (Switzerland) |
Topical treatments (Loceryl), investing in next-gen antifungals |
12.8% |
|
Bausch Health Companies Inc. (Canada) |
Jublia (efinaconazole), dominant in topical solutions |
9.2% |
|
Moberg Pharma AB (Sweden) |
OTC antifungals (Emtrix), expanding in EU & North America |
5.7% |
|
Dr. Reddy’s Laboratories (India) |
Low-cost generics (terbinafine), key player in emerging markets |
7.3% |
|
Glenmark Pharmaceuticals (India) |
Affordable antifungals, strong presence in Asia & Africa |
xx% |
|
Bayer AG (Germany) |
Nail antifungal solutions (Canesten), OTC focus |
xx% |
|
Sanofi S.A. (France) |
Prescription & OTC antifungals, expanding in Latin America |
xx% |
|
Perrigo Company plc (Ireland) |
Store-brand topical antifungals, retail pharmacy dominance |
xx% |
|
Teva Pharmaceutical Industries (Israel) |
Generic terbinafine, major supplier in Europe & U.S. |
xx% |
|
Lupin Limited (India) |
Cost-effective generics, growing in U.S. Medicaid markets |
xx% |
|
Viatris Inc. (U.S.) |
Broad antifungal portfolio, strong in emerging markets |
xx% |
|
Almirall S.A. (Spain) |
Dermatology-focused antifungals, EU market leader |
xx% |
|
Hikma Pharmaceuticals (UK) |
Injectable & oral antifungals, MENA region expansion |
xx% |
|
Mayne Pharma Group (Australia) |
Specialty dermatology products, growing in Australia & U.S. |
xx% |
Below are the areas covered for each company under the top 15 global manufacturers:
In the News
- In March 2024, Novartis AG entered into a partnership with Mycocutix, a German biotech, to jointly develop a novel topical antifungal targeting drug-based strains through clinical trials, and €250 million in joint funding.
- In January 2024, Pfizer Inc. declared the FDA acceptance for an improved formulation of Lamisil, constituting a 32% rapid absorption rate, which is further backed by USD 155 million production expansion.
Author Credits: Radhika Pawar
- Report ID: 7707
- Published Date: Jun 02, 2025
- Report Format: PDF, PPT
